Deal Snapshot: The Swiss major has given Sangamo a cashflow injection in a deal to access two novel technologies to develop treatments for neurodegenerative diseases, including against tau for Alzheimer's.
Who: Roche and Sangamo
What: Roche is licensing Sangamo’s zinc finger epigenetic regulation and AAV capsid delivery technologies to pursue tau and another undisclosed neurology
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Investors welcomed Bavarian Nordic’s and Bayer’s earnings announcements. However, both stock prices declined over the day of their reports as the impact of recent pressures weighed.
Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.
The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.
The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.
The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.
The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.
A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.
